Ignite Creation Date:
2025-12-24 @ 2:34 PM
Ignite Modification Date:
2026-01-02 @ 6:16 PM
Study NCT ID:
NCT02304159
Status:
COMPLETED
Last Update Posted:
2019-04-24
First Post:
2014-11-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Sponsor:
Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-17
First Submit QC Date:
None
Study First Post Date:
2014-12-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-02-04
Results First Submit QC Date:
None
Results First Post Date:
2019-04-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-23
Last Update Post Date:
2019-04-24
Last Update Post Date Type:
ACTUAL